Intraoperative Cholangiography and Risk of Common Bile Duct Injury During Cholecystectomy

David R. Flum, MD, MPH
E. Patchen Dellinger, MD
Allen Cheadle, PhD
Leighton Chan, MD, MPH
Thomas Koepsell, MD, MPH

CHOLECYSTECTOMY IS THE MOST commonly performed elective abdominal surgical procedure in the United States with more than 750,000 performed yearly.1 Injury to the common bile duct (CBD) during cholecystectomy occurs infrequently, but it is an important source of patient morbidity. Serious injuries often require at least 1 surgical repair, and these repairs have variable long-term outcomes.2 Furthermore, CBD injury is the leading cause of medical malpractice claims against general surgeons.3,4

The use of intraoperative cholangiography (IOC), the injection of radiographic contrast material into the cystic duct to evaluate the CBD, may prevent a CBD injury during cholecystectomy. Since Mirizzi5 introduced IOC in the 1930s, its benefit has been extensively debated. Some surgeons advocate routine IOC use6,7 while others advise selective8,9 or no use. Intraoperative cholangiography can provide information about the presence of CBD stones and show a surgical roadmap of the CBD. It can provide an early warning10 for the most serious type of surgical misperception, the misidentification of the CBD as the cystic duct.11,12 Thus, the information obtained from the IOC may prevent and decrease the severity of CBD injuries.12

**Context** Intraoperative cholangiography (IOC) may decrease the risk of common bile duct (CBD) injury during cholecystectomy by helping to avoid misidentification of the CBD.

**Objective** To characterize the relationship of IOC use and CBD injury while controlling for patient and surgeon characteristics.

**Design, Setting, and Patients** Retrospective nationwide cohort analysis of Medicare patients undergoing cholecystectomy from January 1, 1992, to December 31, 1999. Patients were identified using Current Procedural Terminology codes from the Medicare Part B depository. Common bile duct injury was defined by a second surgical procedure to repair the CBD injury within 1 year of cholecystectomy. Surgeon demographic features were obtained from matching the Medicare Part B data to the American Medical Association Physician Masterfile database.

**Main Outcome Measure** Frequency of CBD injury in patients who did and did not have IOC performed during cholecystectomy, controlling for patient-level (age, sex, race, and case complexity) and surgeon-level (surgeon’s age, sex, race, year of surgical procedure, case order, percentage of IOC use in prior surgical procedures, years in medical practice, board certification, and specialization) factors.

**Results** The database search identified 1,570,361 cholecystectomies and 7,911 CBD injuries (0.5%). Common bile duct injury was found in 2,380 (0.39%) of 613,706 patients undergoing cholecystectomy with IOC and in 5,531 (0.58%) of 956,655 patients undergoing cholecystectomy without IOC (unadjusted relative risk, 1.49; 95% confidence interval, 1.42–1.57). After controlling for patient-level factors and surgeon-level factors, the risk of injury was increased when IOC was not used (adjusted relative risk, 1.71; 95% confidence interval, 1.38–2.28). While surgeons performing IOCs routinely had a lower rate of CBD injuries than those who did not, this difference disappeared when IOC was not used.

**Conclusions** In this study of Medicare patients undergoing cholecystectomy in the 1990s, the risk of CBD injury was significantly higher when IOC was not used. Although IOCs may not prevent all CBD injuries, this study suggests that the routine use of IOC may decrease the rate of CBD injury.

JAMA. 2003;289:1639-1644 www.jama.com
Two prior population-based, retrospective studies have suggested a reduction in the risk of CBD injury with IOC use.\textsuperscript{13,14} Unfortunately, these studies had a relatively small population size and could not adjust for important surgeon-level factors. The purpose of this study was to characterize the relationship of IOC use and CBD injury while controlling for patient and surgeon characteristics; specifically, to distinguish the effect of a surgeon performing IOCs routinely from the effect of the IOC itself on the rate of CBD injury.

**METHODS**

**Study Design**

We used a retrospective cohort design, using complete, nationwide Medicare Part B data (January 1, 1992, to December 31, 1999) that contained *Current Procedural Terminology* (CPT) codes pertaining to cholecystectomy and/or biliary tract disease. This study was exempted from University of Washington human subjects review.

**Data Sources and Setting**

Medicare’s Part B files consist of a series of line items, with each line representing a discrete service for which a payment claim was made to Medicare for an individual patient. These data, generated from the medical claims repository, include all billing information for Medicare inpatients and outpatients seen in the fee-for-service arena during the study years. Each billing line has information regarding the physician providing the care, the CPT code for the service performed, associated *International Classification of Diseases, Ninth Revision* (ICD-9)\textsuperscript{15} diagnostic codes, and demographic information about the patient. Medicare’s unique physician identification number was used to match Medicare Part B data to the American Medical Association (AMA) Physician Masterfile database, as previously described.\textsuperscript{16} The AMA Physician Masterfile includes information on physicians/surgeons, such as age, race, sex, specialty in surgery, board certification status, and years in practice since medical school. Of the surgeons identified in the Medicare Part B depository, 2% could not be matched to the AMA Physician Masterfile. A complete-case analysis was performed on all surgeons identified in the AMA Physician Masterfile.

**Subjects**

Patients were defined as having likely CBD injuries if they had undergone a cholecystectomy with IOC (CPT codes 49311, 56341, 47563, 47605, 74300, and/or 74301) or without IOC (CPT codes 49310, 56340, 56342, 47562, 47600, 47610, 47612, or 47620 without codes for IOC) followed by surgical repair of the CBD (CPT codes 47701, 47720, 47721, 47740, 47760, 47765, or 47780) within the subsequent 12 months of cholecystectomy. We excluded patients with diagnoses of hepatobiliary malignancies or choledochal cysts (ICD-9 diagnostic codes 155.1, 156, 156.1, 156.8, and/or 156.9).

**Definition of Variables**

**Patient-Level Covariates.** The modified Charlson comorbidity index (0-3, with 3 indicating greatest comorbidity)\textsuperscript{17} was calculated for each patient based on ICD-9 diagnostic codes from all index and all prior medical records that contained an ICD-9 diagnostic code for biliary tract disease. Medical records with associated ICD-9 diagnostic codes of pancreatitis, CBD stone, cholangitis, sepsis, acute cholecystitis, or CPT codes for CBD exploration, were defined as complex biliary tract disease.

**Surgeon-Level Covariates.** The number of cholecystectomies performed by each surgeon prior to a given cholecystectomy was defined as case order, and this number was used as a marker of surgical experience at that point in time. *Early case order* was defined as the lowest quartile of case orders, that is, the surgeon’s first 20 cholecystectomies. Case order also was considered as a continuous variable. *Routine* and *selective* IOC were defined by the percentage of prior cholecystectomies performed with an IOC. This percentage was considered a marker for the surgeon’s frequency of IOC use. Surgeons who perform routine IOCs were defined as those using IOCs in at least 75% of surgical procedures. Frequency of IOC use also was considered as a continuous variable.

**Statistical Analysis**

Descriptive statistics on patient-level and surgeon-level variables were compared for patients with and without CBD injury and for patients who did or did not undergo IOC (SAS version 7; SAS Institute, Cary, NC). A multivariate logistic regression model was used to analyze the relationship of IOC use and CBD injuries while controlling for clinically relevant covariates (patient-level and surgeon-level variables). Because of the infrequency of CBD injury, the odds ratios approximated the relative risks (RRs). In the first unadjusted model, the sole predictor variable was IOC and the outcome variable was CBD injury. Then this model was augmented to adjust for patient-level covariates (age group, sex, race, and case complexity) and then for both patient-level and surgeon-level covariates (surgeon’s age, race, and sex, year of the surgical procedure, case order, frequency of IOC use in other cholecystectomy cases, specialty in surgery, board certification status, and years in practice since medical school).

We accounted for the potential correlation of data from patients treated by the same surgeon using mixed-model estimating techniques (SAS, PROC GENMOD, SAS Institute, Cary, NC).\textsuperscript{18} Because of the large number of medical records involved in the study, the mixed-model analysis was performed on a 10% random sample. While this analysis did not affect the point estimate, it did modestly widen the confidence intervals (CIs), and the final reported estimates are based on this 10% sample.

**RESULTS**

A total of 1,570,361 Medicare patients underwent cholecystectomy performed by 40,210 physicians between 1992 and 1999. Of the cholecystectomies performed, 76% were classified as laparoscopic cholecystectomy, but this
percentage may not include surgical procedures that started out as laparoscopic cholecystectomies and then were converted to open cholecystectomies. For this reason, the study results did not distinguish between laparoscopic and open cholecystectomies.

Common bile duct injury was identified in 7911 (0.5%) cholecystectomies. Patients who had a CBD injury, compared with patients without CBD injury, had a higher mean (SD) age (73.5 [9.5] years vs 71.4 [10.5] years), were less likely to be female (53.9% vs 62.9%), were more commonly operated on by surgeons performing 1 of their first 20 recorded cholecystectomies (35.1% vs 24.8%), had a higher mean (SD) comorbidity index (0.76 [0.96] vs 0.06 [0.22]), and were more likely to have complex biliary tract disease (14.2% vs 10.9%) (TABLE 1).

Intraoperative cholangiograms were performed in 39% (n=613706) of all patients who underwent a cholecystectomy. Patients who did and did not have an IOC had similar features (TABLE 2). When surgeons infrequently performed IOCs (<25%), the rate of CBD injury was actually higher than when they did not perform IOC (0.78% vs 0.49%, respectively). When surgeons more commonly performed IOCs (25%-75%), the rate of CBD injury was lower than when they did not perform IOC. This association between frequency of IOC use and CBD injury increased in surgeons who performed IOCs routinely (>75%), for whom the rate of CBD injury was approximately 6 times higher than if IOC was not performed (0.26% vs 1.50%).

Use of IOC decreased over time with 44.9% of patients in 1992 but only 35.8% of patients in 1999 having an IOC. Controlling for case order, cholecystectomies after 1997 were 26% less likely to have had an IOC than those before 1997 (odds ratio, 0.74; 95% CI, 0.72-0.77).

**Table 1. Characteristics of Patients With and Without Common Bile Duct (CBD) Injury**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Without CBD Injury</th>
<th>With CBD Injury</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient-level variables</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, mean (SD), y</td>
<td>71.4 (10.5)</td>
<td>73.5 (9.5)</td>
</tr>
<tr>
<td>Sex, % female*</td>
<td>62.9</td>
<td>53.9</td>
</tr>
<tr>
<td>Race, % white/non-Hispanic</td>
<td>88.8</td>
<td>88.2</td>
</tr>
<tr>
<td>Complex biliary tract disease, %</td>
<td>10.9</td>
<td>14.2</td>
</tr>
<tr>
<td>Comorbidity index, mean (SD)*</td>
<td>0.06 (0.22)</td>
<td>0.76 (0.96)</td>
</tr>
<tr>
<td>Surgeon-level variables</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, mean (SD), y*</td>
<td>48.4 (9.5)</td>
<td>47.7 (9.6)</td>
</tr>
<tr>
<td>Sex, % male</td>
<td>96.7</td>
<td>96.6</td>
</tr>
<tr>
<td>Percent performed in the surgeon's first 20 cholecystectomies†</td>
<td>24.8</td>
<td>35.1</td>
</tr>
<tr>
<td>Case order, mean No. (SD)†</td>
<td>64.3 (59.2)</td>
<td>62.9 (61.5)</td>
</tr>
<tr>
<td>General surgeon/surgical specialist, %‡</td>
<td>95.6</td>
<td>96.5</td>
</tr>
<tr>
<td>Surgeon board certified, %*</td>
<td>80.8</td>
<td>82.4</td>
</tr>
<tr>
<td>Years since surgeon graduated from medical school, mean (SD)*</td>
<td>22.1 (9.8)</td>
<td>21.5 (9.6)</td>
</tr>
</tbody>
</table>

*Differences were statistically significant (P<.001).
†Case order among Medicare patients from January 1, 1992, to December 31, 1999.
‡Specialty code designated as general surgeon or other specialist.

**Table 2. Characteristics of Patients With and Without Intraoperative Cholangiography (IOC)**

<table>
<thead>
<tr>
<th>Variables</th>
<th>With IOC (n = 613706)</th>
<th>Without IOC (n = 956655)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient-level variables</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, mean (SD), y*</td>
<td>71.7 (10.3)</td>
<td>71.2 (10.7)</td>
</tr>
<tr>
<td>Sex, % female*</td>
<td>62.6</td>
<td>63.2</td>
</tr>
<tr>
<td>Race, % white/non-Hispanic</td>
<td>88.9</td>
<td>88.8</td>
</tr>
<tr>
<td>Complex biliary tract disease, %</td>
<td>10.9</td>
<td>11.0</td>
</tr>
<tr>
<td>Comorbidity index, mean (SD)*</td>
<td>0.04 (0.22)</td>
<td>0.08 (0.24)</td>
</tr>
<tr>
<td>Surgeon-level variables</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, mean (SD), y*</td>
<td>48.1 (9.3)</td>
<td>48.6 (9.6)</td>
</tr>
<tr>
<td>Sex, % male*</td>
<td>96.8</td>
<td>96.7</td>
</tr>
<tr>
<td>Percent performed in the surgeon's first 20 cholecystectomies†</td>
<td>24.6</td>
<td>25.0</td>
</tr>
<tr>
<td>Case order, mean No. (SD)†</td>
<td>70.5 (61.3)</td>
<td>66.6 (67.7)</td>
</tr>
<tr>
<td>General surgeon/surgical specialist, %‡</td>
<td>95.6</td>
<td>95.6</td>
</tr>
<tr>
<td>Surgeon board certified, %*</td>
<td>82.6</td>
<td>79.6</td>
</tr>
<tr>
<td>Years since surgeon graduated from medical school, mean (SD), y*</td>
<td>21.8 (9.6)</td>
<td>22.3 (9.6)</td>
</tr>
</tbody>
</table>

*Differences were statistically significant (P<.001).
†Case order among Medicare patients from January 1, 1992, to December 31, 1999.
‡Specialty code designated as general surgeon or other specialist.

The effect of using IOC in a given patient was different among surgeons in different IOC frequency of use categories (TABLE 3). When surgeons infrequently performed IOCs (<25%), the rate of CBD injury was actually higher than when they did not perform IOC (0.78% vs 0.49%, respectively). When surgeons more commonly performed IOCs (25%-75%), the rate of CBD injury was lower than when they did not perform IOC. This association between frequency of IOC use and CBD injury increased in surgeons who performed IOCs routinely (>75%), for whom the rate of CBD injury was approximately 6 times higher than if IOC was not performed (0.26% vs 1.50%).
COMMENT

The results of our study indicated that not using an IOC during cholecystectomy was associated with a 50% to 70% increase in the risk of CBD injury. Even after controlling for important patient-level and surgeon-level factors, we found that the adjusted RR of CBD injury during cholecystectomy was 71% higher when IOC was not used. Surgeons who routinely performed IOCs had a lower rate of patient CBD injuries than those who performed IOCs less than routinely, but only when IOC was used. This study suggests that routine use of IOC during cholecystectomy may decrease the rate of CBD injury.

For years, some surgeons have speculated that IOC use can decrease both the absolute rate and the seriousness of CBD injuries,11,12 but because of the infrequent nature of CBD injury, no properly conducted controlled trials have evaluated this hypothesis. Because of the large sample size required for such a trial, conducting large observational studies may be the only feasible way to address the relationship of CBD injury and IOC use. The Medicare Part B depository was an attractive way to obtain information about a large number of individuals, and because IOC has a unique surgical CPT code, the information was readily available.

Previous observational studies have addressed the issue of CBD injury and IOC use. For example, Fletcher et al14 demonstrated a 50% reduction in the rate of CBD injury when IOC was used among a cohort of patients in Western Australia during the early 1990s. Our group examined the frequency of CBD injury in Washington State from 1991 to 1997 and found that for laparoscopic cholecystectomies, the risk of CBD injury was 67% higher when an IOC was not used.15 Surgeon experience modified the effect of the IOC on CBD injury, and among surgeons performing their first 20 laparoscopic cholecystectomies, the risk of CBD injury was 2.2 times higher when IOC was not used.

Our findings in this study extend our previous work in that we have examined the largest cohort to date and we have controlled for important patient-level and surgeon-level variables. Another important distinction of our current analysis from previous observational studies is that we have evaluated a surgeon’s previous use of IOC and its relationship to CBD injury. Surgeons who routinely use IOC may be different in other ways that offer protection from CBD injury. For example, if surgeons who routinely use IOC are generally more cautious or more protective of the CBD and have a lower rate of CBD injury than those who infrequently use IOC, observational studies, such as these cited herein, might ascribe this lower rate to the increased use of IOC.

Of all surgeons, we found that those who routinely used IOC had the lowest rates of CBD injury, but only in those cases in which they actually used IOC. In fact, among surgeons who routinely used IOC, when a decision was made not to use IOC (or when an IOC could not be obtained) we saw a significantly higher rate of CBD injury. This increased rate may indicate that in certain clinical situations, both a higher risk of CBD injury and a greater likelihood of not having an IOC performed exist. In Mirizzi syndrome19,20 in which the gall bladder is inflamed and adjoined to the CBD or when anatomic variants are present, an IOC may be difficult to perform and the patient may be at a higher risk for injury. Interestingly, surgeons who infrequently use IOC were shown to have a higher rate of CBD injury when using the IOC. This higher rate may be because they used IOC at later points in the surgical procedure, specifically when a CBD injury was already suspected. Alternatively, the performance of the IOC may cause damage to the CBD in certain situations encountered by surgeons who infrequently perform IOC.

While observational studies cannot show that IOC use prevents CBD injury, several components to this association are compelling. The rate of CBD injury was higher when IOC was not used. This association persisted when controlling for many important patient-level and surgeon-level factors and showed a stronger association when these factors were accounted for. In addition, this study is the third population-based analysis that has shown this effect, and all 3 studies have demonstrated a similar magnitude of effect.11,14 If this association is causal, then a change in surgeon behavior to more frequently perform IOC could potentially decrease the rate of CBD injury.

It may be argued that the absolute risk reduction associated with IOC (ap-
proportionately 0.2%) does not warrant the added time and cost. However, recent cost analyses\textsuperscript{21,22} suggest significant gross savings, and in a modeled analysis, IOC routinely performed was associated with a cost/life-year saved of approximately $13000.\textsuperscript{22} Routine application of IOC might be considered unnecessary because only certain patients are at high risk for CBD injury, and in this group, selective use of IOC has been advocated.\textsuperscript{8,9} However, until there is accurate prediction of which patients are more likely to have CBD injury, the recommendation for routine IOC application may remain the best approach.

A final argument against routine use of IOC deals with the rarity of CBD injury, and that many surgeons practice their entire careers without using IOC and without resulting in CBD injuries.\textsuperscript{9} Because of the relative infrequency of CBD injury, the benefit of IOC use may not be detectable within the case series of an individual surgeon. Nonetheless, when considering CBD injury from a public health perspective, the experience of the community at large is more important than the experience of individual surgeons.

The routine use of IOCs will not prevent all CBD injuries. An IOC has to be correctly performed and interpreted to assist the surgeon in identifying the CBD, and injuries can occur after an IOC has been performed. Furthermore, the rate of other types of injuries, such as those caused by cautery and excessive traction on the bile duct, may not be affected by increased use of IOC. Use of IOC also is not without risk, although the risk is quite small. For example, a case of an allergic reaction to the contrast used in IOC has been reported.\textsuperscript{23}

Other less-invasive approaches to evaluating the biliary tract tree aimed at decreasing the rate of CBD injury exist. For example, intraoperative ultrasonography of the biliary tract tree may be used to obtain images of the bile duct, and in limited series, this imaging procedure has been helpful in evaluating biliary tract anatomy.\textsuperscript{49,53} Other technical interventions that may reduce the risk of CBD injury include beginning the dissection on the laterally retracted gallbladder rather than the cystic duct/CBD junction,\textsuperscript{9,25} avoiding blood in the surgical field, early identification of a surgical safety zone,\textsuperscript{26} using a 30° angled laparoscope,\textsuperscript{27} and having a low threshold for conversion to open cholecystectomy.\textsuperscript{30} All these interventions should be considered, but because of the infrequent nature of CBD injury none of these approaches has been shown, in an appropriately powered study, to reduce the rate of CBD injury.

This study has several limitations. Our study, as with all observational studies, was unable to control for other unmeasured variables, such as hospital characteristics, that may affect CBD injury. While a recent study demonstrated that low hospital volume was associated with adverse outcome,\textsuperscript{31} hospital factors have not been related to either the rate of CBD injury or the use of IOC.\textsuperscript{13} Another possible limitation of this study relates to the quality of the administrative coding. While the accuracy of clinical conclusions drawn from administrative data may be imperfect, our findings closely match those based on more clinical sources.\textsuperscript{32-34} For example, a rate of CBD injury of 0.5% matches that identified by a recently published review of more than 114000 patients from 40 large case series.\textsuperscript{33} Direct validation of the use of administrative codes for detection of CBD injury found this data source to be accurate\textsuperscript{36} despite an earlier report that pointed out the pitfalls of using so-called "injury codes"\textsuperscript{37} for the detection of these injuries. Furthermore, in a study\textsuperscript{38} of patients in Maryland, there was a high level of agreement (96%-97%) between Part B Medicare data and physicians’ office medical records regarding procedures.

Several unique features of this dataset also limit the conclusions of the study. Using administrative codes to evaluate cholecystectomy did not allow for the clear distinction of open and laparoscopic procedures, possibly resulting in inconsistent coding of converted laparoscopic procedures. A laparoscopic procedure in which a CBD injury was suspected, prompting a change to an open procedure, might have been coded as an open procedure. This would spuriously increase the rate of CBD injury in open procedures and decrease this rate in laparoscopic procedures.

This study could not determine the intent of IOC use and could not distinguish among IOCs performed to prevent injury, used to detect injury when one was suspected, and intended to detect a CBD stone. Furthermore, this study focused on major CBD injuries by defining injury as a second surgical event within 12 months following cholecystectomy. In fact, many minor CBD injuries may be treated with endoscopic or percutaneous interventions. Therefore, the rate of CBD injury detailed in this study may underestimate the actual rate of CBD injuries in this population and minor injuries were probably missed after IOC use.

We selected a follow-up interval extending to 1 year after cholecystectomy for surgical repair of CBD injury in determining CBD injury because in one of the larger case series of repairs of the CBD, all patients were operated on within 1 year after cholecystectomy.\textsuperscript{11} By not including repairs that occurred after 1 year we may have undercounted actual CBD injuries.

Additionally, case order in this study was derived from all cholecystectomy procedures performed in patients covered by Medicare fee-for-service from 1992 to 1999. The case order variable likely undercounted surgeon experience by not including surgical procedures performed before 1992 and those performed in patients who were not covered through Medicare fee-for-service. Therefore, case order is likely defined on the basis of nonconsecutive cases and was considered a proxy marker of surgeon experience rather than a direct measure of this experience. Similarly, the frequency of IOC use by the surgeon should be considered a proxy for the frequency of IOC use performed by any given surgeon because it was determined by Medicare Part B data only. Lastly, some medical records may have been incomplete, for example, if the pa-
tient died before having a CBD injury re-
paired or if their health care coverage
shifted to a health maintenance organi-
zation after the cholecystectomy was per-
formed. The impact of these factors on
the analysis is unclear.

In conclusion, among Medicare pa-
tients in the 1990s, the rate of CBD in-
jury during cholecystectomy was sig-
nificantly higher when IOC was not
used. This study suggests that the broader use of IOC may decrease the rate of CBD injury.

Author Contributions: Study concept and design: Flum, Chan. Acquisition of the data: Chan. Analysis and interpretation of the data: Flum, Dellinger, Cheadle, Chan, Koepsell. Drafting of the manuscript: Flum, Dellinger, Cheadle, Chan, Koepsell. Critical revision of the manuscript: Flum, Dellinger, Chan, Koepsell.

Statistical expertise: Flum, Chan, Koepsell. Administrative, Technical or Material Support: Cheadle, Chan, Koepsell. Study supervision: Dellinger, Chan.

Funding/Support: The Robert Wood Johnson Foun-
dation provided funding for this project.

Disclaimer: The views expressed in this article are those of the authors and not necessarily those of the Cen-
ters for Medicare and Medicaid Services, the Robert
Wood Johnson Foundation, or the University of Wash-
ington.

Acknowledgment: We gratefully acknowledge the contributions of Cecilia Prela, PharmD, and Shelli K.
Beaver, MS, to this project.

REFERENCES
1. Centers for Disease Control and Prevention, Na-
tional Center for Health Statistics, Division of Health Care Statistics, Hospital Care Statistics Branch. Avail-
able at: http://www.cdc.gov/nchs/data/tables/2002
2. Johnson SR, Koehler A, Pennington LK, Hanto DW.
Long-term results of surgical repair of bile duct inju-
ries following laparoscopic cholecystectomy. Sur-
3. Physician Insurers Association of America. Exhibit
2000. Rockville, Md: Physician Insurers Association of
America; 2000:15.
4. Physician Insurers Association of America. Table 4.
In: Laparoscopic Injury Study 2000. Rockville Md: Phy-
sician Insurers Association of America; 2000:11.
5. Mirziti PL. Operative cholangiography. Surg Gyn-
col Oncol. 1937;65:702-710.
6. Soper NJ, Brunt LM. The case for routine opera-
tive cholangiography during laparoscopic cho-
7. Vezakis A, Davides W, Ammon BI, Martin IG, Larvin
M, McMahan MJ. Intraoperative cholangiography dur-
ing laparoscopic cholecystectomy. Surg Endosc. 2000;
14:1118-1122.
8. Ladoci LT, Benitez LD, Filippone DR, Nance FC.
Intraoperative cholangiography in laparoscopic cho-
lecystectomy: a review of 734 consecutive cases. Am
sis of perioperative cholangiography in one thou-
sand laparoscopic cholecystectomies. Surgery. 1997;
122:817-821.
10. Archer SB, Brown DW, Smith CD, Branum GD,
Hunter JG. Bile duct injury during laparoscopic cho-
2001;234:549-558.
11. Woods MS, Traverso LW, Kozarek RA, et al. Char-
acteristics of biliary tract complications during lapa-
roscopic cholecystectomy: a multi-institutional study.
12. Woods MS, Traverso LW, Kozarek RA, et al. Bili-
ary tract complications of laparoscopic cholecystec-
tomy are detected more frequently with routine in-
traoperative cholangiography. Surg Endosc. 1995;9:
1076-1080.
13. Flum DR, Koepsell T, Heagerty P, Sinanen M, Del-
linger EP. Common bile duct injury during lapa-
roscopic cholecystectomy and the use of intraoperative
cholangiography: adverse outcome or preventable er-
14. Fletcher DR, Hobbs MS, Tan P, et al. Complica-
tions of cholecystectomy: risks of the laparoscopic ap-
proach and protective effects of operative changi-
229:449-457.
15. JCD-9 CM Expert. Ingenix, Inc: West Valley City,
Utah; 2000.
16. Baldwin LM, Adameche W, Klabunde CN, Ken-
ward K, Daniel J, Warren J. Linking physician char-
acteristics and medicare claims data: issues in data avail-
bility, quality, and measurement. Med Care. 2002;
40(8 suppl IV):82-95.
17. Deyo RA, Cherkin DC,bert MA. Assessing a clini-
cal comorbidity index for use with ICD-9-CM admin-
istrative databases. J Clin Epidemiol. 1992;45:613-
619.
18. Zeger SL, Liang KY, Albert PS. Models for longi-
tudinal data: generalized estimating equation ap-
19. Posta CG. Unexpected Mirizzi anatomy: a major haz-
ard to the common bile duct during laparoscopic cho-
20. Cortin S, Dalla Valle R, Zincola R, Botta GC. Un-
diagnosed Mirizzi’s syndrome: a word of caution for lapa-
roscopic surgeons—a report of three cases and review of
9:197-203.
Is intraoperative cholangiography during laparo-
2001;182:663-669.
22. Flum DR, Flowers C, Venstra D. A cost analysis of
cholangiograms in the prevention of common bile duct injuy.
23. Moskovitz AH, Bush WH Jr, Horvath KD. Ana-
phylactoid reaction to intraoperative cholangiogram:
report of a case, review of literature, and guidelines for
ing laparoscopic cholecystectomy: review of the lit-
erature and a comparison with open intraoperative ul-
25. Birth M, Carroll BJ, Delinikolas K, Eichler M, Wei-
er H. Recognition of laparoscopic bile duct injuries
by intraoperative ultrasonography. Surg Endosc. 1996;
10:794-797.
26. Mahmud S, Masaud M, Canna K, Nissar AH. Fun-
27. Katkhouda N, Mavor E, Mason RJ. Visual iden-
tification of the cystic duct–CBD junction during lapa-
roscopic cholecystectomy (visual cholangiography): an
additional step for prevention of CBD injuries. Surg End-
a “safety zone” for the safety of laparoscopic cholecys-
29. Asbun H, Rossi RL. Techniques of laparoscopic cho-
lecystectomy: the difficult operation. Surg Clin North
Am. 1994;74:755-775; discussion 777-780.
30. Roviaro GC, Maciocco M, Rebuffat C, et al. Com-
plications following cholecystectomy. J R Coll Surg Ed-
31. Birnley JD, Siewers AE, Finlayson EV, et al. Hos-
pital volume and surgical mortality in the United States.
32. Cepot J, Evennec I, Aerts R, et al. The dramatic re-
ality of biliary tract injury during laparoscopic cholecys-
tectomy: an anonymous multicenter Belgian survey of
33. Zuggenhi J, Weyhl H, Metzger A, Bucher M, Fei E, Klaber C. Complications of laparoscopic cho-
lecystectomy in Switzerland: a prospective 3-year study
of 10,174 patients: Swiss Association of Laparo-
12:1303-1310.
34. Wherry DC, Marooh MR, Malanoski MP, Hetz
SP, Rich NW. An external audit of laparoscopic cho-
lecystectomy in the steady state performed in medi-
cal treatment facilities of the Department of De-
35. Vecchio R, MacFadyen BV, Latteri S. Comparison of
bile duct injuries using record linkage: a validated
study of complications following cholecystectomy.
37. Taylor B. Common bile duct injury during laparo-
scopic cholecystectomy in Ontario: does ICD-9 coding
38. Fowles JB, Lawthers AG, Weiner JP, Garnick DW,
Petrie DS, Palmer RH. Agreement between physi-
cians’ office records and Medicare Part B claims data.

1644 JAMA, April 2, 2003—Vol 289, No. 13 (Reprinted) ©2003 American Medical Association. All rights reserved.